CCTG at ASCO Gastrointestinal Cancer Symposium

The 2026 ASCO Gastrointestinal Cancer Symposium was held on January 8-10, 2026 in San Francisco, California see all the CCTG Abstracts below.

CCTG CRC.10/ NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

Session Type:    Trials in Progress Poster Session 

Session Title:     Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Citation:               J Clin Oncol 44, 2026 (suppl 2; abstr TPS256)

Abstract #:          TPS256

Abstract:              Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).

Authors:              Christopher Lieu, Guan Yu, Scott Kopetz, Shannon Puhalla, Peter Lucas, Ibrahim Halil Sahin, Dustin Deming, Philip Philip, Theodore Hong, Yesenia Rojas-Khalil, Jonathan Loree, Norman Wolmark, Greg Yothers, Thomas George, Arvind Dasari

Abstract Link:    https://www.asco.org/abstracts-presentations/255264/abstract 

CCTG CRC.6/ CALGB (Alliance), SWOG 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer

Session Type:    Poster Session

Session Title:     Poster Session C: Cancers of the Colon, Rectum, and Anus 

Citation:              J Clin Oncol 44, 2026 (suppl 2; abstr 163)

Abstract #:          163

Abstract:              Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.

Authors:              George Q. Zhang, Chao Ma, Qian Shi, Jonathan A. Nowak, Levi D. Pederson, Tyler Twombly, Juha P. Väyrynen       Melissa M. Zhao, Yasutoshi Takashima, Ardaman Shergill Pankaj Kumar, Felix Couture, J. P. Kuebler, Smitha S. Krishnamurthi, Benjamin R. Tan, Shuji Ogino, Justin Brown, Adham A. Jurdi, Anthony F. Shields, Jeffrey A. Meyerhardt

Link:                    https://www.asco.org/abstracts-presentations/255344 

CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies

Session Type:    Poster Session

Session Title:     Poster Session C: Cancers of the Colon, Rectum, and Anus 

Citation:              J Clin Oncol 44, 2026 (suppl 2; abstr 196)

Abstract #:          196

Abstract:              The interplay of HLA diversity and copy loss, T-cell profiles, and immunotherapy efficacy in colorectal adenocarcinoma.

Authors:              Andrew Galbraith, Emma Titmuss, James T. Topham, Dongsheng Tu, Daniel Renouf, David Schaeffer, Sharlene Gill, Derek J Jonker, Joao Paulo Solar Vasconcelos, Eric X Chen, Chris J O’Callaghan, Jonathan M Loree

Link:                    https://www.asco.org/abstracts-presentations/255266